CignaMedium ImpactCoverage
Cigna Pathwell Specialty: Updates to the drug list
Published March 31, 2026Effective March 9, 2026
AI Summary
Cigna removed six denosumab medications from the Pathwell Specialty drug list effective March 9, 2026. These medications no longer require administration by Pathwell Specialty designated providers, but standard prior authorization for medical necessity still applies per patient plan benefits.
Action Required
Immediately: Billing team must update systems to remove Pathwell Specialty provider requirements for Prolia (denosumab), Bildyos, Conexxence, Enoby, Jubbonti, and Stoboclo. Verify standard prior authorization processes are in place for medical necessity according to patient plan benefits. Check coverage policies at CignaforHCP.com for current medical necessity requirements.
Plan Types
Commercial
Specialties
endocrinology, rheumatology, oncology, ortho